Advancing AI-assisted drug discovery with the translational power of EEG via PsychoGenics

eCube® is a pharmaco-EEG platform that collects data from novel compounds and subsequently compares their signatures against a comprehensive database of marketed drugs. This process enables the prediction of the therapeutic utility of these compounds. eCube® works in synergy with SmartCube®, and the combined results from both platforms provide PsychoGenics‘ partners with enhanced confidence in the accuracy of our predictions.

• – eCube^® provides a uniform testing platform to record actigraphy and quantitative EEG (qEEG) from different brain regions of unanesthetized mice before and after drug administration.
• – Like the SmartCube^® process, raw data and the derived features from the brain signals and biometrics are used to train a machine learning classifier, which can be used to identify novel compounds with the desired EEG profile and activity.
• – eCube^® can also be used to phenotype disease models, including autism spectrum disorders, rare genetic epilepsies, Huntington’s disease, Alzheimer’s disease, and more.

Find out more.